Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:Butylparaben
go back to main search page
Accession:CHEBI:88542 term browser browse the term
Synonyms:related_synonym: 4-(Butoxycarbonyl)phenol;   4-Hydroxybenzoic acid butyl ester;   Aseptoform butyl;   Benzoic acid, 4-hydroxy-, butyl ester;   Benzoic acid, p-hydroxy-, butyl ester;   Butoben;   Butyl 4-hydroxybenzoate;   Butyl butex;   Butyl chemosept;   Butyl par asept;   Butyl paraben;   Butyl parahydroxybenzoate;   Butyl parahydroxybenzoate (JP15);   Butyl parahydroxybenzoate (TN);   Butyl parasept;   Butyl tegosept;   Butyl-p-hydroxybenzoate;   Butylparaben (NF);   Butylparaben (TN);   Butylparaben [usan];   FEMA 2203;   Formula=C11H14O3;   InChI=1S/C11H14O3/c1-2-3-8-14-11(13)9-4-6-10(12)7-5-9/h4-7,12H,2-3,8H2,1H3;   InChIKey=QFOHBWFCKVYLES-UHFFFAOYSA-N;   Lexgard b;   N-Butyl 4-hydroxybenzoate;   N-Butyl hydroxybenzoate;   N-Butyl parahydroxybenzoate;   N-Butyl-p-hydroxybenzoate;   N-Butyl-paraben;   Nipabutyl;   P-Hydroxy butyl benzoate;   P-Hydroxybenzoic acid N-butyl ester;   P-Hydroxybenzoic acid butyl ester;   P-Hydroxybenzoic butyl ester;   Parasept;   Preserval b;   SMILES=CCCCOC(C1=CC=C(C=C1)O)=O;   SPF;   Solbrol b;   Tegosept B
 alt_id: CHEBI:31329
 xref: CAS:94-26-8;   HMDB:HMDB0032575;   KEGG:D01420;   LINCS:LSM-2161
 xref_mesh: MESH:C038091
 xref: PMID:18294789


show annotations for term's descendants           Sort by:
 
Butylparaben term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aars2 alanyl-tRNA synthetase 2, mitochondrial increases expression ISO butylparaben results in increased expression of AARS2 mRNA CTD PMID:17121429 NCBI chr 9:17,869,301...17,881,762
Ensembl chr 9:17,869,124...17,880,706
JBrowse link
G Abat 4-aminobutyrate aminotransferase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ABAT mRNA CTD PMID:25607892 NCBI chr10:7,093,406...7,200,439
Ensembl chr10:7,093,405...7,200,499
JBrowse link
G Acan aggrecan decreases expression ISO butylparaben results in decreased expression of ACAN mRNA CTD PMID:28527915 NCBI chr 1:140,762,758...140,824,441
Ensembl chr 1:140,762,758...140,824,441
JBrowse link
G Acsl6 acyl-CoA synthetase long-chain family member 6 increases expression ISO butylparaben results in increased expression of ACSL6 mRNA CTD PMID:17121429 NCBI chr10:39,654,771...39,717,592
Ensembl chr10:39,655,455...39,719,312
JBrowse link
G Actn1 actinin, alpha 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ACTN1 mRNA CTD PMID:25607892 NCBI chr 6:103,376,557...103,470,497
Ensembl chr 6:103,375,799...103,470,555
JBrowse link
G Adam17 ADAM metallopeptidase domain 17 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA CTD PMID:25607892 NCBI chr 6:43,400,525...43,448,280
Ensembl chr 6:43,400,528...43,448,280
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions
increases expression
ISO butylparaben promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]
butylparaben results in increased expression of ADIPOQ mRNA
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [butylparaben results in increased expression of ADIPOQ mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [butylparaben results in increased expression of ADIPOQ mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of ADIPOQ mRNA]; Mifepristone inhibits the reaction [butylparaben results in increased expression of ADIPOQ mRNA]
CTD PMID:22956630, PMID:31016361 NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
JBrowse link
G Adm adrenomedullin decreases expression ISO butylparaben results in decreased expression of ADM mRNA CTD PMID:17121429 NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
JBrowse link
G Alpl alkaline phosphatase, biomineralization associated decreases expression
multiple interactions
ISO butylparaben results in decreased expression of ALPL mRNA
NR3C1 protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]; PPARG protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]
CTD PMID:28527915 NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537
JBrowse link
G Ar androgen receptor affects binding
affects expression
decreases expression
EXP butylparaben binds to AR protein
butylparaben affects the expression of AR protein
butylparaben results in decreased expression of AR mRNA; butylparaben results in decreased expression of AR protein
CTD PMID:20371976, PMID:26888303, PMID:27444704 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Arhgap9 Rho GTPase activating protein 9 increases expression ISO butylparaben results in increased expression of ARHGAP9 mRNA CTD PMID:17121429 NCBI chr 7:70,612,650...70,620,900
Ensembl chr 7:70,612,103...70,620,890
JBrowse link
G Atf6 activating transcription factor 6 increases expression ISO butylparaben results in increased expression of ATF6 protein CTD PMID:29319206 NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
JBrowse link
G Atm ATM serine/threonine kinase affects expression ISO butylparaben affects the expression of ATM mRNA CTD PMID:24481588 NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
JBrowse link
G Atp5mg ATP synthase membrane subunit g increases expression ISO butylparaben results in increased expression of ATP5L mRNA CTD PMID:17121429 NCBI chr 8:49,220,441...49,227,273
Ensembl chr 8:49,220,443...49,227,273
JBrowse link
G Atr ATR serine/threonine kinase increases expression ISO butylparaben results in increased expression of ATR mRNA CTD PMID:24481588 NCBI chr 8:103,673,578...103,770,886
Ensembl chr 8:103,673,411...103,770,947
JBrowse link
G Bcl2l1 Bcl2-like 1 increases expression ISO butylparaben results in increased expression of BCL2L1 mRNA; butylparaben results in increased expression of BCL2L1 protein CTD PMID:24481588 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of BDNF mRNA CTD PMID:25607892 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
JBrowse link
G Bglap bone gamma-carboxyglutamate protein decreases expression ISO butylparaben results in decreased expression of BGLAP mRNA CTD PMID:28527915 NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
JBrowse link
G Bsn bassoon (presynaptic cytomatrix protein) multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of BSN mRNA CTD PMID:25607892 NCBI chr 8:116,873,721...116,965,396
Ensembl chr 8:116,873,721...116,965,396
JBrowse link
G Cacna1a calcium voltage-gated channel subunit alpha1 A multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1A mRNA CTD PMID:25607892 NCBI chr19:25,453,236...25,749,550
Ensembl chr19:25,526,751...25,749,550
JBrowse link
G Cacna1c calcium voltage-gated channel subunit alpha1 C multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA1C mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1C mRNA CTD PMID:25607892 NCBI chr 4:150,635,808...151,270,790
Ensembl chr 4:150,641,066...150,829,913
JBrowse link
G Cacna1d calcium voltage-gated channel subunit alpha1 D multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA1D mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1D mRNA CTD PMID:25607892 NCBI chr16:6,110,294...6,405,022
Ensembl chr16:6,112,150...6,405,117
JBrowse link
G Cacna1e calcium voltage-gated channel subunit alpha1 E multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1E mRNA CTD PMID:25607892 NCBI chr13:71,899,445...72,534,992
Ensembl chr13:71,906,702...72,367,980
JBrowse link
G Cacna1f calcium voltage-gated channel subunit alpha1 F multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1F mRNA CTD PMID:25607892 NCBI chr  X:15,712,709...15,741,135
Ensembl chr  X:15,712,713...15,741,103
JBrowse link
G Cacna1g calcium voltage-gated channel subunit alpha1 G multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNA1G mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1G mRNA CTD PMID:25607892 NCBI chr10:82,129,071...82,197,828
Ensembl chr10:82,129,506...82,197,848
JBrowse link
G Cacna1h calcium voltage-gated channel subunit alpha1 H multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1H mRNA CTD PMID:25607892 NCBI chr10:14,730,932...14,789,201
Ensembl chr10:14,730,941...14,788,617
JBrowse link
G Cacna1i calcium voltage-gated channel subunit alpha1 I multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNA1I mRNA CTD PMID:25607892 NCBI chr 7:121,521,787...121,619,300
Ensembl chr 7:121,511,097...121,619,283
JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA2D1 mRNA CTD PMID:25607892 NCBI chr 4:15,706,974...16,130,848
Ensembl chr 4:15,710,417...16,130,848
JBrowse link
G Cacna2d2 calcium voltage-gated channel auxiliary subunit alpha2delta 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D2 mRNA CTD PMID:25607892 NCBI chr 8:116,154,661...116,285,643
Ensembl chr 8:116,154,736...116,284,985
JBrowse link
G Cacna2d3 calcium voltage-gated channel auxiliary subunit alpha2delta 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA2D3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D3 mRNA CTD PMID:25607892 NCBI chr16:4,871,348...5,795,825
Ensembl chr16:4,871,650...5,795,825
JBrowse link
G Cacnb1 calcium voltage-gated channel auxiliary subunit beta 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB1 mRNA CTD PMID:25607892 NCBI chr10:85,954,138...85,974,764
Ensembl chr10:85,954,138...85,974,651
JBrowse link
G Cacnb2 calcium voltage-gated channel auxiliary subunit beta 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA CTD PMID:25607892 NCBI chr17:81,673,862...82,019,219
Ensembl chr17:81,798,756...82,017,682
JBrowse link
G Cacnb3 calcium voltage-gated channel auxiliary subunit beta 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNB3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB3 mRNA CTD PMID:25607892 NCBI chr 7:140,311,120...140,324,902
Ensembl chr 7:140,315,368...140,324,902
JBrowse link
G Cacng2 calcium voltage-gated channel auxiliary subunit gamma 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNG2 mRNA CTD PMID:25607892 NCBI chr 7:119,228,112...119,353,332
Ensembl chr 7:119,228,102...119,352,605
JBrowse link
G Cacng5 calcium voltage-gated channel auxiliary subunit gamma 5 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG5 mRNA CTD PMID:25607892 NCBI chr10:96,122,240...96,166,606
Ensembl chr10:96,123,397...96,131,880
JBrowse link
G Cacng6 calcium voltage-gated channel auxiliary subunit gamma 6 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNG6 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG6 mRNA CTD PMID:25607892 NCBI chr 1:64,307,684...64,322,124
Ensembl chr 1:64,305,438...64,321,241
JBrowse link
G Cacng8 calcium voltage-gated channel auxiliary subunit gamma 8 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG8 mRNA CTD PMID:25607892 NCBI chr 1:64,330,106...64,350,338
Ensembl chr 1:64,330,106...64,350,338
JBrowse link
G Calb2 calbindin 2 increases expression ISO butylparaben results in increased expression of CALB2 mRNA CTD PMID:17121429 NCBI chr19:41,482,743...41,509,617
Ensembl chr19:41,482,728...41,509,658
JBrowse link
G Camk2b calcium/calmodulin-dependent protein kinase II beta multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CAMK2B mRNA CTD PMID:25607892 NCBI chr14:86,208,876...86,297,727
Ensembl chr14:86,208,901...86,297,652
JBrowse link
G Cask calcium/calmodulin dependent serine protein kinase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CASK mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CASK mRNA CTD PMID:25607892 NCBI chr  X:9,815,652...10,156,155
Ensembl chr  X:9,815,652...10,156,155
JBrowse link
G Casp8 caspase 8 increases expression ISO butylparaben results in increased expression of CASP8 protein CTD PMID:24481588 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Cat catalase decreases activity
multiple interactions
EXP butylparaben results in decreased activity of CAT protein
butylparaben inhibits the reaction [Triclosan results in increased activity of CAT protein]
CTD PMID:29350491 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccna1 cyclin A1 increases expression ISO butylparaben results in increased expression of CCNA1 mRNA CTD PMID:24481588 NCBI chr 2:144,456,689...144,503,570
Ensembl chr 2:144,458,153...144,467,912
JBrowse link
G Ccna2 cyclin A2 increases expression ISO butylparaben results in increased expression of CCNA2 mRNA CTD PMID:24481588 NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
JBrowse link
G Ccnb2 cyclin B2 increases expression ISO butylparaben results in increased expression of CCNB2 mRNA CTD PMID:24481588 NCBI chr 8:76,847,972...76,861,165 JBrowse link
G Ccnd1 cyclin D1 increases expression ISO butylparaben results in increased expression of CCND1 mRNA CTD PMID:23524099, PMID:24481588 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd3 cyclin D3 affects expression
decreases expression
ISO butylparaben affects the expression of CCND3 mRNA
butylparaben results in decreased expression of CCND3 mRNA
CTD PMID:24481588 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
JBrowse link
G Ccne1 cyclin E1 affects expression ISO butylparaben affects the expression of CCNE1 mRNA CTD PMID:24481588 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Ccne2 cyclin E2 increases expression ISO butylparaben results in increased expression of CCNE2 mRNA CTD PMID:24481588 NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406
JBrowse link
G Cd44 CD44 molecule (Indian blood group) multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CD44 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CD44 mRNA CTD PMID:25607892 NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
JBrowse link
G Cdc25a cell division cycle 25A increases expression ISO butylparaben results in increased expression of CDC25A mRNA CTD PMID:24481588 NCBI chr 8:117,953,223...117,971,552
Ensembl chr 8:117,953,444...117,971,519
JBrowse link
G Cdk2 cyclin dependent kinase 2 increases expression ISO butylparaben results in increased expression of CDK2 mRNA CTD PMID:24481588 NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
JBrowse link
G Cdk4 cyclin-dependent kinase 4 increases expression ISO butylparaben results in increased expression of CDK4 mRNA CTD PMID:24481588 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Cdk6 cyclin-dependent kinase 6 affects expression ISO butylparaben affects the expression of CDK6 mRNA CTD PMID:24481588 NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A decreases expression ISO butylparaben results in decreased expression of CDKN1A mRNA; butylparaben results in decreased expression of CDKN1A protein CTD PMID:24481588 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions
increases expression
ISO 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of CEBPA mRNA]; Mifepristone inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of CEBPA mRNA]; Rimonabant inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA] CTD PMID:22956630, PMID:27659731, PMID:28527915 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Celf5 CUGBP, Elav-like family member 5 increases expression ISO butylparaben results in increased expression of CELF5 mRNA CTD PMID:17121429 NCBI chr 7:11,095,449...11,119,941
Ensembl chr 7:11,095,468...11,119,941
JBrowse link
G Chrdl1 chordin-like 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CHRDL1 mRNA CTD PMID:25607892 NCBI chr  X:114,554,359...114,658,975
Ensembl chr  X:114,554,359...114,658,931
JBrowse link
G Chst1 carbohydrate sulfotransferase 1 increases expression ISO butylparaben results in increased expression of CHST1 mRNA CTD PMID:17121429 NCBI chr 3:81,441,785...81,512,829
Ensembl chr 3:81,498,022...81,512,807
JBrowse link
G Cntn3 contactin 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN3 mRNA CTD PMID:25607892 NCBI chr 4:134,783,671...135,159,309
Ensembl chr 4:134,784,668...135,069,970
JBrowse link
G Cntn4 contactin 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN4 mRNA CTD PMID:25607892 NCBI chr 4:137,785,166...138,787,527
Ensembl chr 4:138,269,142...138,787,525
JBrowse link
G Col10a1 collagen type X alpha 1 chain decreases expression ISO butylparaben results in decreased expression of COL10A1 mRNA CTD PMID:28527915 NCBI chr20:41,180,295...41,190,664
Ensembl chr20:41,184,287...41,189,633
JBrowse link
G Col2a1 collagen type II alpha 1 chain decreases expression ISO butylparaben results in decreased expression of COL2A1 mRNA CTD PMID:28527915 NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
JBrowse link
G Col8a1 collagen type VIII alpha 1 chain increases expression ISO butylparaben results in increased expression of COL8A1 mRNA CTD PMID:17121429 NCBI chr11:44,877,690...45,006,203
Ensembl chr11:44,877,859...45,007,891
JBrowse link
G Cops2 COP9 signalosome subunit 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of COPS2 mRNA CTD PMID:25607892 NCBI chr 3:118,109,394...118,137,125
Ensembl chr 3:118,109,406...118,137,191
JBrowse link
G Cyba cytochrome b-245 alpha chain increases expression ISO butylparaben results in increased expression of CYBA mRNA CTD PMID:17121429 NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
JBrowse link
G Cycs cytochrome c, somatic increases expression ISO butylparaben results in increased expression of CYCS protein CTD PMID:29319206 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 decreases expression EXP butylparaben results in decreased expression of CYP11A1 mRNA; butylparaben results in decreased expression of CYP11A1 protein CTD PMID:26888303 NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
JBrowse link
G Cyp11b2 cytochrome P450, family 11, subfamily b, polypeptide 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CYP11B1 mRNA CTD PMID:25607892 NCBI chr 7:116,248,759...116,255,205
Ensembl chr 7:116,156,219...116,255,167
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CYP17A1 mRNA CTD PMID:25607892 NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 decreases expression
increases expression
increases activity
multiple interactions
affects expression
EXP
ISO
butylparaben results in decreased expression of CYP19A1 mRNA
butylparaben results in increased expression of CYP19A1 mRNA
butylparaben results in decreased expression of CYP19A1 mRNA; butylparaben results in decreased expression of CYP19A1 protein
butylparaben results in increased activity of CYP19A1 protein
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CYP19A1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CYP19A1 mRNA
butylparaben affects the expression of CYP19A1 protein
CTD PMID:23744433, PMID:25607892, PMID:26888303, PMID:27122241, PMID:30817981 NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
decreases activity
ISO
EXP
[butylparaben co-treated with triclocarban] results in increased expression of CYP1A1 mRNA
butylparaben results in decreased activity of CYP1A1 protein
CTD PMID:23524099, PMID:27432241 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases activity EXP butylparaben results in decreased activity of CYP1A2 protein CTD PMID:27432241 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression
multiple interactions
ISO butylparaben results in increased expression of CYP1B1 mRNA
butylparaben promotes the reaction [bisphenol A results in increased expression of CYP1B1 mRNA]
CTD PMID:23524099 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 decreases activity EXP butylparaben results in decreased activity of CYP2B1 protein CTD PMID:27432241 NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 decreases activity EXP butylparaben results in decreased activity of CYP2C11 protein CTD PMID:27432241 NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases activity EXP butylparaben results in decreased activity of CYP2E1 protein CTD PMID:27432241 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Cyp3a62 cytochrome P450, family 3, subfamily a, polypeptide 62 decreases activity EXP butylparaben results in decreased activity of CYP3A62 protein CTD PMID:27432241 NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
JBrowse link
G Dcc DCC netrin 1 receptor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DCC mRNA CTD PMID:25607892 NCBI chr18:66,518,213...67,629,801
Ensembl chr18:66,523,120...67,224,566
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO butylparaben results in increased expression of DDIT3 protein CTD PMID:29319206 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein increases expression ISO butylparaben results in increased expression of DIABLO mRNA CTD PMID:24481588 NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLG1 mRNA CTD PMID:25607892 NCBI chr11:72,164,566...72,378,895
Ensembl chr11:72,163,749...72,378,895
JBrowse link
G Dlg4 discs large MAGUK scaffold protein 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DLG4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLG4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of DLG4 mRNA CTD PMID:25607892 NCBI chr10:56,625,845...56,655,543
Ensembl chr10:56,627,411...56,653,599
JBrowse link
G Dlgap3 DLG associated protein 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of DLGAP3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLGAP3 mRNA CTD PMID:25607892 NCBI chr 5:145,234,757...145,304,536
Ensembl chr 5:145,257,714...145,304,536
JBrowse link
G Dnmt3a DNA methyltransferase 3 alpha multiple interactions
increases expression
EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DNMT3A mRNA
butylparaben results in increased expression of DNMT3A mRNA
CTD PMID:25607892, PMID:26888303 NCBI chr 6:28,205,375...28,346,052
Ensembl chr 6:28,235,695...28,340,577
JBrowse link
G Dnmt3b DNA methyltransferase 3 beta increases expression EXP butylparaben results in increased expression of DNMT3B mRNA CTD PMID:26888303 NCBI chr 3:149,131,541...149,170,061
Ensembl chr 3:149,131,785...149,208,786
JBrowse link
G Dpp6 dipeptidyl peptidase like 6 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of DPP6 mRNA CTD PMID:25607892 NCBI chr 4:4,021,021...4,943,675
Ensembl chr 4:4,021,008...4,473,307
JBrowse link
G E2f1 E2F transcription factor 1 affects expression ISO butylparaben affects the expression of E2F1 mRNA CTD PMID:24481588 NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
JBrowse link
G E2f3 E2F transcription factor 3 affects expression ISO butylparaben affects the expression of E2F3 mRNA CTD PMID:24481588 NCBI chr17:36,334,136...36,408,831
Ensembl chr17:36,334,147...36,408,831
JBrowse link
G Efna4 ephrin A4 increases expression ISO butylparaben results in increased expression of EFNA4 mRNA CTD PMID:17121429 NCBI chr 2:188,655,920...188,660,179
Ensembl chr 2:188,655,912...188,660,179
JBrowse link
G Egf epidermal growth factor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of EGF mRNA CTD PMID:25607892 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Elp6 elongator acetyltransferase complex subunit 6 increases expression ISO butylparaben results in increased expression of ELP6 mRNA CTD PMID:17121429 NCBI chr 8:118,525,770...118,541,074
Ensembl chr 8:118,525,682...118,541,073
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA CTD PMID:25607892 NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB3 mRNA CTD PMID:25607892 NCBI chr 7:2,989,202...3,010,610
Ensembl chr 7:2,989,340...3,010,350
JBrowse link
G Erbb4 erb-b2 receptor tyrosine kinase 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of ERBB4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of ERBB4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB4 mRNA CTD PMID:25607892 NCBI chr 9:75,021,790...76,178,936
Ensembl chr 9:75,021,790...75,528,644
JBrowse link
G Ercc2 ERCC excision repair 2, TFIIH core complex helicase subunit increases expression ISO butylparaben results in increased expression of ERCC2 mRNA CTD PMID:17121429 NCBI chr 1:80,293,574...80,307,334
Ensembl chr 1:80,293,566...80,307,344
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 increases expression ISO butylparaben results in increased expression of ERN1 protein CTD PMID:29319206 NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
JBrowse link
G Esr1 estrogen receptor 1 affects binding
increases activity
decreases expression
multiple interactions
decreases activity
increases expression
decreases methylation
ISO
EXP
butylparaben binds to ESR1 protein; butylparaben metabolite binds to ESR1 protein
butylparaben results in increased activity of ESR1 protein
butylparaben results in decreased expression of ESR1 mRNA; butylparaben results in decreased expression of ESR1 protein
butylparaben inhibits the reaction [Estradiol binds to ESR1 protein]; Fulvestrant inhibits the reaction [butylparaben results in decreased expression of ESR1 mRNA]; Fulvestrant inhibits the reaction [butylparaben results in decreased expression of ESR1 protein]
butylparaben results in decreased activity of ESR1 protein
butylparaben results in increased expression of ESR1 mRNA; butylparaben results in increased expression of ESR1 protein
[butylparaben co-treated with NRG1 protein] promotes the reaction [ESR1 protein binds to MYC enhancer]; butylparaben binds to and results in increased activity of ESR1 protein; Fulvestrant inhibits the reaction [butylparaben results in increased activity of ESR1 protein]
butylparaben results in decreased methylation of ESR1 promoter
CTD PMID:11193391, PMID:15204698, PMID:19063592, PMID:19654335, PMID:20074635, PMID:20132880, PMID:20362049, PMID:20435135, PMID:22562034, PMID:23524099, PMID:23567241, PMID:25012808, PMID:25128701, PMID:26502914, PMID:26888303, PMID:27444704, PMID:29945225 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Esr2 estrogen receptor 2 affects binding
multiple interactions
increases expression
decreases expression
EXP
ISO
butylparaben binds to ESR2 protein
butylparaben binds to and results in increased activity of ESR2 protein
butylparaben results in increased expression of ESR2 mRNA
butylparaben results in decreased expression of ESR2 mRNA
butylparaben results in increased expression of ESR2 mRNA; butylparaben results in increased expression of ESR2 protein
CTD PMID:11193391, PMID:18648085, PMID:20132880, PMID:23567241, PMID:25128701, PMID:26888303 NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
JBrowse link
G Esrrg estrogen-related receptor gamma multiple interactions ISO butylparaben inhibits the reaction [afimoxifene inhibits the reaction [ESRRG protein binds to NCOA2 protein]] CTD PMID:23583298 NCBI chr13:106,063,799...106,683,353
Ensembl chr13:106,463,368...106,683,436
JBrowse link
G Faah fatty acid amide hydrolase decreases activity ISO
EXP
butylparaben results in decreased activity of FAAH protein CTD PMID:27659731 NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
JBrowse link
G Faahl fatty-acid amide hydrolase-like decreases activity ISO butylparaben results in decreased activity of FAAH protein CTD PMID:27659731 NCBI chr 5:134,330,204...134,349,400
Ensembl chr 5:134,331,929...134,348,995
JBrowse link
G Fabp4 fatty acid binding protein 4 multiple interactions
increases expression
ISO butylparaben promotes the reaction [Dexamethasone results in increased expression of FABP4 mRNA]; NR3C1 protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA]; PPARG mutant form inhibits the reaction [butylparaben results in increased expression of FABP4 mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA] CTD PMID:22956630, PMID:24155963, PMID:27659731, PMID:28527915 NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
JBrowse link
G Fasn fatty acid synthase increases expression
multiple interactions
ISO butylparaben results in increased expression of FASN mRNA
butylparaben promotes the reaction [Dexamethasone results in increased expression of FASN mRNA]
CTD PMID:22956630 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR1 mRNA CTD PMID:25607892 NCBI chr16:71,265,390...71,319,046
Ensembl chr16:71,266,248...71,319,449
JBrowse link
G Fgfr2 fibroblast growth factor receptor 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR2 mRNA CTD PMID:25607892 NCBI chr 1:200,590,951...200,696,946
Ensembl chr 1:200,590,953...200,696,928
JBrowse link
G Fshb follicle stimulating hormone subunit beta decreases secretion
decreases expression
EXP butylparaben results in decreased secretion of FSHB protein
butylparaben results in decreased expression of FSHB protein
CTD PMID:27444704, PMID:29350491 NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
JBrowse link
G Fus FUS RNA binding protein increases expression ISO butylparaben results in increased expression of FUS mRNA CTD PMID:17121429 NCBI chr 1:199,412,805...199,426,705
Ensembl chr 1:199,412,834...199,426,702
JBrowse link
G Fyn FYN proto-oncogene, Src family tyrosine kinase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of FYN mRNA CTD PMID:25607892 NCBI chr20:44,436,354...44,630,316
Ensembl chr20:44,436,403...44,630,317
JBrowse link
G Gabra4 gamma-aminobutyric acid type A receptor subunit alpha 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GABRA4 mRNA CTD PMID:25607892 NCBI chr14:39,154,072...39,230,994
Ensembl chr14:39,154,529...39,231,695
JBrowse link
G Gabrb1 gamma-aminobutyric acid type A receptor subunit beta1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GABRB1 mRNA CTD PMID:25607892 NCBI chr14:38,631,192...39,112,598
Ensembl chr14:38,643,385...39,112,600
JBrowse link
G Gls glutaminase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GLS mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GLS mRNA CTD PMID:25607892 NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
JBrowse link
G Gper1 G protein-coupled estrogen receptor 1 increases expression ISO butylparaben results in increased expression of GPER1 mRNA; butylparaben results in increased expression of GPER1 protein CTD PMID:17121429, PMID:26253279 NCBI chr12:17,309,122...17,315,267
Ensembl chr12:17,309,834...17,311,112
JBrowse link
G Greb1 growth regulating estrogen receptor binding 1 multiple interactions
increases expression
ISO Fulvestrant inhibits the reaction [butylparaben metabolite results in increased expression of GREB1 mRNA]; Fulvestrant inhibits the reaction [butylparaben results in increased expression of GREB1 mRNA]
butylparaben metabolite results in increased expression of GREB1 mRNA; butylparaben results in increased expression of GREB1 mRNA
CTD PMID:17121429, PMID:29945225 NCBI chr 6:41,932,941...42,002,770
Ensembl chr 6:41,932,244...42,002,819
JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA CTD PMID:25607892 NCBI chr 2:179,584,302...179,704,629
Ensembl chr 2:179,584,308...179,704,629
JBrowse link
G Gria4 glutamate ionotropic receptor AMPA type subunit 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIA4 mRNA CTD PMID:25607892 NCBI chr 8:1,548,145...2,045,874
Ensembl chr 8:1,548,146...2,045,817
JBrowse link
G Grik2 glutamate ionotropic receptor kainate type subunit 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIK2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK2 mRNA CTD PMID:25607892 NCBI chr20:53,791,428...54,517,691
Ensembl chr20:53,789,760...54,517,709
JBrowse link
G Grik4 glutamate ionotropic receptor kainate type subunit 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIK4 mRNA CTD PMID:25607892 NCBI chr 8:46,804,134...47,237,546
Ensembl chr 8:46,806,147...47,094,352
JBrowse link
G Grik5 glutamate ionotropic receptor kainate type subunit 5 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK5 mRNA CTD PMID:25607892 NCBI chr 1:81,885,516...81,946,731
Ensembl chr 1:81,885,521...81,946,714
JBrowse link
G Grin1 glutamate ionotropic receptor NMDA type subunit 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of GRIN1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN1 mRNA CTD PMID:25607892 NCBI chr 3:2,507,745...2,534,664
Ensembl chr 3:2,506,896...2,534,663
JBrowse link
G Grin2b glutamate ionotropic receptor NMDA type subunit 2B multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN2B mRNA CTD PMID:25607892 NCBI chr 4:169,541,620...170,000,216
Ensembl chr 4:169,560,387...169,999,873
JBrowse link
G Grin2c glutamate ionotropic receptor NMDA type subunit 2C multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN2C mRNA CTD PMID:25607892 NCBI chr10:103,798,290...103,816,923
Ensembl chr10:103,798,291...103,816,287
JBrowse link
G Grin2d glutamate ionotropic receptor NMDA type subunit 2D multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN2D mRNA CTD PMID:25607892 NCBI chr 1:101,819,068...101,859,146
Ensembl chr 1:101,820,461...101,856,881
JBrowse link
G Grin3a glutamate ionotropic receptor NMDA type subunit 3A multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN3A mRNA CTD PMID:25607892 NCBI chr 5:64,928,620...65,073,012
Ensembl chr 5:64,928,620...65,073,012
JBrowse link
G Grip1 glutamate receptor interacting protein 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIP1 mRNA CTD PMID:25607892 NCBI chr 7:64,672,723...64,854,939
Ensembl chr 7:64,672,722...64,864,404
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases phosphorylation ISO butylparaben results in decreased phosphorylation of GSK3B protein CTD PMID:29319206 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Hes6 hes family bHLH transcription factor 6 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of HES6 mRNA CTD PMID:25607892 NCBI chr 9:98,549,698...98,551,438
Ensembl chr 9:98,549,705...98,551,438
JBrowse link
G Hexb hexosaminidase subunit beta multiple interactions EXP zinc chloride inhibits the reaction [butylparaben results in increased secretion of HEXB protein] CTD PMID:15272608 NCBI chr 2:27,983,925...28,003,260
Ensembl chr 2:27,984,117...28,003,186
JBrowse link
G Hps6 HPS6, biogenesis of lysosomal organelles complex 2 subunit 3 increases expression ISO butylparaben results in increased expression of HPS6 mRNA CTD PMID:17121429 NCBI chr 1:265,761,818...265,764,427
Ensembl chr 1:265,761,738...265,764,437
JBrowse link
G Hr HR, lysine demethylase and nuclear receptor corepressor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of HR mRNA CTD PMID:25607892 NCBI chr15:52,241,801...52,261,276
Ensembl chr15:52,241,801...52,261,276
JBrowse link
G Hsd17b10 hydroxysteroid (17-beta) dehydrogenase 10 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of HSD17B10 mRNA CTD PMID:25607892 NCBI chr  X:21,696,796...21,699,241
Ensembl chr  X:21,696,772...21,699,241
JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of HSD17B8 mRNA CTD PMID:25607892 NCBI chr20:3,817,212...3,819,316
Ensembl chr20:3,817,179...3,819,235
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression ISO butylparaben results in increased expression of HSPA5 protein CTD PMID:29319206 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Hspb8 heat shock protein family B (small) member 8 increases expression ISO butylparaben results in increased expression of HSPB8 mRNA CTD PMID:23524099 NCBI chr12:45,905,371...45,920,014
Ensembl chr12:45,905,371...45,920,013
JBrowse link
G Igdcc3 immunoglobulin superfamily, DCC subclass, member 3 increases expression ISO butylparaben results in increased expression of IGDCC3 mRNA CTD PMID:17121429 NCBI chr 8:70,630,546...70,685,882
Ensembl chr 8:70,630,767...70,684,115
JBrowse link
G Igf1r insulin-like growth factor 1 receptor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of IGF1R mRNA CTD PMID:25607892 NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
JBrowse link
G Igf2r insulin-like growth factor 2 receptor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of IGF2R mRNA CTD PMID:25607892 NCBI chr 1:48,176,095...48,264,482
Ensembl chr 1:48,176,106...48,264,477
JBrowse link
G Il17rb interleukin 17 receptor B increases expression ISO butylparaben results in increased expression of IL17RB mRNA CTD PMID:17121429 NCBI chr16:6,064,287...6,077,978
Ensembl chr16:6,064,288...6,077,978
JBrowse link
G Il1rapl1 interleukin 1 receptor accessory protein-like 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of IL1RAPL1 mRNA CTD PMID:25607892 NCBI chr  X:55,439,388...57,004,865
Ensembl chr  X:55,439,578...56,765,893
JBrowse link
G Incenp inner centromere protein increases expression ISO butylparaben results in increased expression of INCENP mRNA CTD PMID:17121429 NCBI chr 1:225,923,448...225,953,384
Ensembl chr 1:225,925,773...225,952,516
JBrowse link
G Ins2 insulin 2 multiple interactions ISO butylparaben promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased secretion of TNFRSF11B protein]; butylparaben promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein] CTD PMID:31016361 NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
JBrowse link
G Jag1 jagged canonical Notch ligand 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of JAG1 mRNA CTD PMID:25607892 NCBI chr 3:130,079,361...130,114,781
Ensembl chr 3:130,079,361...130,114,770
JBrowse link
G Kcnc1 potassium voltage-gated channel subfamily C member 1 increases expression ISO butylparaben results in increased expression of KCNC1 mRNA CTD PMID:17121429 NCBI chr 1:102,414,352...102,456,718
Ensembl chr 1:102,414,625...102,456,411
JBrowse link
G Kcnf1 potassium voltage-gated channel modifier subfamily F member 1 increases expression ISO butylparaben results in increased expression of KCNF1 mRNA CTD PMID:17121429 NCBI chr 6:42,471,060...42,473,738
Ensembl chr 6:42,471,066...42,473,738
JBrowse link
G Krt8 keratin 8 increases expression ISO butylparaben results in increased expression of KRT8 mRNA CTD PMID:17121429 NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
JBrowse link
G Krt82 keratin 82 increases expression ISO butylparaben results in increased expression of KRT82 mRNA CTD PMID:17121429 NCBI chr 7:143,196,282...143,206,138
Ensembl chr 7:143,196,068...143,206,265
JBrowse link
G Lef1 lymphoid enhancer binding factor 1 increases expression ISO butylparaben results in increased expression of LEF1 mRNA CTD PMID:17121429 NCBI chr 2:236,232,115...236,345,061
Ensembl chr 2:236,233,239...236,345,056
JBrowse link
G Lep leptin decreases expression
increases expression
ISO butylparaben results in decreased expression of LEP mRNA
butylparaben results in increased expression of LEP mRNA
CTD PMID:22956630 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions
decreases secretion
decreases expression
EXP butylparaben promotes the reaction [Triclosan results in decreased secretion of LHB protein]; Triclosan promotes the reaction [butylparaben results in decreased secretion of LHB protein]
butylparaben results in decreased expression of LHB protein
CTD PMID:27444704, PMID:29350491 NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
JBrowse link
G Lin7a lin-7 homolog A, crumbs cell polarity complex component multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of LIN7A mRNA CTD PMID:25607892 NCBI chr 7:49,429,613...49,627,835
Ensembl chr 7:49,385,705...49,656,856
JBrowse link
G Lmod1 leiomodin 1 increases expression ISO butylparaben results in increased expression of LMOD1 mRNA CTD PMID:17121429 NCBI chr13:52,147,099...52,189,835
Ensembl chr13:52,147,555...52,190,228
JBrowse link
G Lpin1 lipin 1 multiple interactions
increases expression
ISO [Dexamethasone co-treated with butylparaben] results in increased expression of LPIN1 mRNA; NR3C1 mutant form inhibits the reaction [butylparaben results in increased expression of LPIN1 mRNA] CTD PMID:22956630 NCBI chr 6:41,796,214...41,905,149
Ensembl chr 6:41,799,749...41,870,046
JBrowse link
G Lrrc29 leucine rich repeat containing 29 increases expression ISO butylparaben results in increased expression of LRRC29 mRNA CTD PMID:17121429 NCBI chr19:37,266,782...37,282,076
Ensembl chr19:37,266,783...37,281,933
JBrowse link
G Magi2 membrane associated guanylate kinase, WW and PDZ domain containing 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of MAGI2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MAGI2 mRNA CTD PMID:25607892 NCBI chr 4:10,995,241...12,472,423
Ensembl chr 4:10,995,234...11,610,518
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation ISO butylparaben results in increased phosphorylation of MAPK1 protein CTD PMID:26253279, PMID:29319206 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation ISO butylparaben results in increased phosphorylation of MAPK3 protein CTD PMID:26253279, PMID:29319206 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Masp1 mannan-binding lectin serine peptidase 1 increases expression ISO butylparaben results in increased expression of MASP1 mRNA CTD PMID:17121429 NCBI chr11:80,736,424...80,806,278
Ensembl chr11:80,736,576...80,803,382
JBrowse link
G Mdga2 MAM domain containing glycosylphosphatidylinositol anchor 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of MDGA2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MDGA2 mRNA CTD PMID:25607892 NCBI chr 6:88,442,620...89,292,454
Ensembl chr 6:88,447,749...88,917,070
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MET mRNA CTD PMID:25607892 NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
JBrowse link
G Mmp3 matrix metallopeptidase 3 multiple interactions EXP [enzacamene co-treated with octylmethoxycinnamate co-treated with bisphenol A co-treated with butylparaben] results in increased expression of MMP3 mRNA CTD PMID:25305543 NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression
multiple interactions
ISO butylparaben results in increased expression of MYC mRNA
[butylparaben co-treated with NRG1 protein] promotes the reaction [ESR1 protein binds to MYC enhancer]; [NRG1 protein co-treated with butylparaben] results in increased expression of MYC protein; butylparaben promotes the reaction [NRG1 protein results in increased expression of MYC mRNA]; NRG1 protein promotes the reaction [butylparaben results in increased expression of MYC mRNA]
CTD PMID:26502914 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Ncoa2 nuclear receptor coactivator 2 multiple interactions ISO butylparaben inhibits the reaction [afimoxifene inhibits the reaction [ESRRG protein binds to NCOA2 protein]] CTD PMID:23583298 NCBI chr 5:5,466,544...5,696,540
Ensembl chr 5:5,616,483...5,694,598
JBrowse link
G Nf1 neurofibromin 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NF1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NF1 mRNA CTD PMID:25607892 NCBI chr10:66,732,460...66,928,706
Ensembl chr10:66,690,133...66,928,903
JBrowse link
G Nlgn1 neuroligin 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NLGN1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NLGN1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NLGN1 mRNA CTD PMID:25607892 NCBI chr 2:111,057,291...111,973,681
Ensembl chr 2:111,057,291...111,793,326
JBrowse link
G Notch2 notch receptor 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NOTCH2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NOTCH2 mRNA CTD PMID:25607892 NCBI chr 2:200,187,184...200,320,403
Ensembl chr 2:200,187,179...200,320,215
JBrowse link
G Notch4 notch receptor 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NOTCH4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NOTCH4 mRNA CTD PMID:25607892 NCBI chr20:4,329,794...4,353,868
Ensembl chr20:4,329,811...4,353,785
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression EXP
ISO
butylparaben results in increased expression of NR1I2 mRNA CTD PMID:31472229 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases expression EXP butylparaben results in increased expression of NR1I3 mRNA CTD PMID:31472229 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 multiple interactions
increases activity
increases response to substance
ISO NR3C1 mutant form inhibits the reaction [butylparaben results in increased expression of LPIN1 mRNA]; NR3C1 protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]; NR3C1 protein promotes the reaction [butylparaben results in decreased expression of SPP1 mRNA]; NR3C1 protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA]; NR3C1 protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]
butylparaben results in increased activity of NR3C1 protein
[butylparaben co-treated with propylparaben] results in increased activity of NR3C1 protein; [Diethylhexyl Phthalate co-treated with butylparaben co-treated with propylparaben] results in increased activity of NR3C1 protein; [Diethylhexyl Phthalate co-treated with butylparaben co-treated with tetramethrin co-treated with propylparaben] results in increased activity of NR3C1 protein; [Diethylhexyl Phthalate co-treated with butylparaben co-treated with tetramethrin] results in increased activity of NR3C1 protein; [Diethylhexyl Phthalate co-treated with butylparaben] results in increased activity of NR3C1 protein
NR3C1 protein results in increased susceptibility to butylparaben
CTD PMID:22956630, PMID:25448277, PMID:28527915 NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
JBrowse link
G Nr3c2 nuclear receptor subfamily 3, group C, member 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NR3C2 mRNA CTD PMID:25607892 NCBI chr19:34,408,275...34,761,003
Ensembl chr19:34,448,289...34,752,695
JBrowse link
G Nr5a1 nuclear receptor subfamily 5, group A, member 1 decreases expression EXP butylparaben results in decreased expression of NR5A1 mRNA CTD PMID:27122241 NCBI chr 3:22,998,900...23,020,441
Ensembl chr 3:22,999,616...23,020,441
JBrowse link
G Nrcam neuronal cell adhesion molecule multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRCAM mRNA CTD PMID:25607892 NCBI chr 6:64,297,843...64,867,408
Ensembl chr 6:64,297,888...64,864,996
JBrowse link
G Nrg1 neuregulin 1 multiple interactions EXP
ISO
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NRG1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NRG1 mRNA
[butylparaben co-treated with NRG1 protein] promotes the reaction [ESR1 protein binds to MYC enhancer]; [NRG1 protein co-treated with butylparaben] results in increased expression of MYC protein; butylparaben promotes the reaction [NRG1 protein results in increased expression of MYC mRNA]; NRG1 protein promotes the reaction [butylparaben results in increased expression of MYC mRNA]
CTD PMID:25607892, PMID:26502914 NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
JBrowse link
G Nrxn1 neurexin 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRXN1 mRNA CTD PMID:25607892 NCBI chr 6:13,886,757...15,191,660
Ensembl chr 6:13,886,740...15,191,660
JBrowse link
G Nrxn2 neurexin 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRXN2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NRXN2 mRNA CTD PMID:25607892 NCBI chr 1:221,792,191...221,908,047
Ensembl chr 1:221,792,221...221,908,049
JBrowse link
G Ntrk1 neurotrophic receptor tyrosine kinase 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NTRK1 mRNA CTD PMID:25607892 NCBI chr 2:187,143,568...187,160,373
Ensembl chr 2:187,143,568...187,160,373
JBrowse link
G Ntrk2 neurotrophic receptor tyrosine kinase 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NTRK2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NTRK2 mRNA CTD PMID:25607892 NCBI chr17:5,934,651...6,245,778
Ensembl chr17:5,933,729...6,244,676
JBrowse link
G Ntrk3 neurotrophic receptor tyrosine kinase 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NTRK3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NTRK3 mRNA CTD PMID:25607892 NCBI chr 1:139,890,537...140,262,503
Ensembl chr 1:139,890,560...140,262,503
JBrowse link
G Nxph3 neurexophilin 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NXPH3 mRNA CTD PMID:25607892 NCBI chr10:83,329,263...83,332,929
Ensembl chr10:83,328,410...83,332,851
JBrowse link
G Otof otoferlin increases expression ISO butylparaben results in increased expression of OTOF mRNA CTD PMID:17121429 NCBI chr 6:27,328,343...27,424,864
Ensembl chr 6:27,328,406...27,424,864
JBrowse link
G Pcdha3 protocadherin alpha 3 increases expression ISO butylparaben results in increased expression of PCDHA3 mRNA CTD PMID:17121429 NCBI chr18:29,966,245...30,215,896 JBrowse link
G Pcdhgc3 protocadherin gamma subfamily C, 3 increases expression ISO butylparaben results in increased expression of PCDHGC3 mRNA CTD PMID:17121429 NCBI chr18:30,954,552...30,971,113
Ensembl chr18:30,913,842...30,969,361
JBrowse link
G Pex14 peroxisomal biogenesis factor 14 increases expression ISO butylparaben results in increased expression of PEX14 mRNA CTD PMID:17121429 NCBI chr 5:165,782,895...165,918,445
Ensembl chr 5:165,782,895...165,918,445
JBrowse link
G Pgr progesterone receptor multiple interactions
increases expression
EXP
ISO
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PGR mRNA; Fulvestrant inhibits the reaction [butylparaben results in increased expression of PGR mRNA]; Fulvestrant inhibits the reaction [butylparaben results in increased expression of PGR protein]
Silver inhibits the reaction [butylparaben results in increased expression of PGR mRNA]
butylparaben results in increased expression of PGR mRNA; butylparaben results in increased expression of PGR protein
CTD PMID:17121429, PMID:19654335, PMID:23524099, PMID:25128701, PMID:25607892, PMID:29074358 NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
JBrowse link
G Pi4ka phosphatidylinositol 4-kinase alpha increases expression ISO butylparaben results in increased expression of PI4KA mRNA CTD PMID:17121429 NCBI chr11:87,858,323...87,975,549
Ensembl chr11:87,858,453...87,973,422
JBrowse link
G Plin1 perilipin 1 increases expression
multiple interactions
ISO butylparaben results in increased expression of PLIN1 mRNA
NR3C1 protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]; PPARG mutant form inhibits the reaction [butylparaben results in increased expression of PLIN1 mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]
CTD PMID:22956630, PMID:28527915 NCBI chr 1:141,458,907...141,470,927
Ensembl chr 1:141,458,181...141,471,010
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases expression EXP butylparaben results in increased expression of PPARA mRNA CTD PMID:31472229 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression
multiple interactions
increases response to substance
increases activity
ISO butylparaben results in increased expression of PPARG mRNA
butylparaben binds to and results in increased activity of PPARG protein
PPARG protein results in increased susceptibility to butylparaben
butylparaben results in increased activity of PPARG protein
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [butylparaben results in increased expression of PPARG mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [butylparaben results in increased expression of PPARG mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of PPARG mRNA]; Mifepristone inhibits the reaction [butylparaben results in increased expression of PPARG mRNA]; PPARG mutant form inhibits the reaction [butylparaben results in increased expression of FABP4 mRNA]; PPARG mutant form inhibits the reaction [butylparaben results in increased expression of PLIN1 mRNA]; PPARG protein inhibits the reaction [butylparaben results in decreased expression of SPP1 mRNA]; PPARG protein promotes the reaction [butylparaben binds to and results in increased activity of PPARG protein]; PPARG protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of CEBPA mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]
CTD PMID:22956630, PMID:24155963, PMID:27659731, PMID:28527915 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PRKN mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of PRKN mRNA CTD PMID:25607892 NCBI chr 1:48,880,015...50,069,998 JBrowse link
G Prlr prolactin receptor increases expression ISO butylparaben results in increased expression of PRLR mRNA CTD PMID:17121429 NCBI chr 2:60,131,410...60,325,686
Ensembl chr 2:60,131,776...60,325,692
JBrowse link
G Pyroxd2 pyridine nucleotide-disulphide oxidoreductase domain 2 decreases expression ISO butylparaben results in decreased expression of PYROXD2 mRNA CTD PMID:17121429 NCBI chr 1:261,961,164...261,987,029
Ensembl chr 1:261,961,379...261,986,759
JBrowse link
G Reln reelin multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of RELN mRNA CTD PMID:25607892 NCBI chr 4:9,347,533...9,774,257
Ensembl chr 4:9,347,528...9,773,670
JBrowse link
G Robo1 roundabout guidance receptor 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ROBO1 mRNA CTD PMID:25607892 NCBI chr11:9,079,291...10,146,302
Ensembl chr11:9,642,365...10,143,317
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions
decreases phosphorylation
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [butylparaben results in decreased phosphorylation of RPS6 protein] CTD PMID:29319206 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation
multiple interactions
ISO butylparaben results in decreased phosphorylation of RPS6KB1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [butylparaben results in decreased phosphorylation of RPS6KB1 protein]; U 0126 inhibits the reaction [butylparaben results in decreased phosphorylation of RPS6KB1 protein]
CTD PMID:29319206 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Runx2 RUNX family transcription factor 2 decreases expression ISO butylparaben results in decreased expression of RUNX2 mRNA CTD PMID:28527915 NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
JBrowse link
G S100g S100 calcium binding protein G multiple interactions
increases expression
EXP Fulvestrant inhibits the reaction [butylparaben results in increased expression of S100G mRNA]; Fulvestrant inhibits the reaction [butylparaben results in increased expression of S100G protein]
butylparaben results in increased expression of S100G mRNA; butylparaben results in increased expression of S100G protein
CTD PMID:19654335 NCBI chr  X:33,442,820...33,445,714
Ensembl chr  X:33,443,186...33,445,709
JBrowse link
G Shank1 SH3 and multiple ankyrin repeat domains 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SHANK1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK1 mRNA CTD PMID:25607892 NCBI chr 1:100,297,137...100,344,377
Ensembl chr 1:100,297,152...100,344,377
JBrowse link
G Shank2 SH3 and multiple ankyrin repeat domains 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SHANK2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SHANK2 mRNA CTD PMID:25607892 NCBI chr 1:217,149,156...217,593,950
Ensembl chr 1:217,151,166...217,592,763
JBrowse link
G Shank3 SH3 and multiple ankyrin repeat domains 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK3 mRNA CTD PMID:25607892 NCBI chr 7:130,474,278...130,534,679
Ensembl chr 7:130,474,279...130,534,679
JBrowse link
G Siah2 siah E3 ubiquitin protein ligase 2 decreases expression ISO butylparaben results in decreased expression of SIAH2 mRNA CTD PMID:17121429 NCBI chr 2:148,874,151...148,891,900
Ensembl chr 2:148,874,151...148,891,900
JBrowse link
G Slc17a7 solute carrier family 17 member 7 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC17A7 mRNA CTD PMID:25607892 NCBI chr 1:101,161,265...101,172,292
Ensembl chr 1:101,161,252...101,173,174
JBrowse link
G Slc1a1 solute carrier family 1 member 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A1 mRNA CTD PMID:25607892 NCBI chr 1:246,955,017...247,035,159
Ensembl chr 1:246,954,980...247,037,056
JBrowse link
G Slc1a2 solute carrier family 1 member 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLC1A2 mRNA CTD PMID:25607892 NCBI chr 3:92,518,679...92,665,731
Ensembl chr 3:92,640,752...92,665,644
JBrowse link
G Slc1a3 solute carrier family 1 member 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLC1A3 mRNA CTD PMID:25607892 NCBI chr 2:57,860,881...57,935,363
Ensembl chr 2:57,860,834...57,935,363
JBrowse link
G Slc1a6 solute carrier family 1 member 6 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A6 mRNA CTD PMID:25607892 NCBI chr 7:13,730,101...13,758,170
Ensembl chr 7:13,730,253...13,751,271
JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO butylparaben inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
JBrowse link
G Slit1 slit guidance ligand 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SLIT1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLIT1 mRNA CTD PMID:25607892 NCBI chr 1:260,843,481...260,992,366
Ensembl chr 1:260,843,483...260,992,366
JBrowse link
G Smc1a structural maintenance of chromosomes 1A increases expression ISO butylparaben results in increased expression of SMC1A mRNA CTD PMID:17121429 NCBI chr  X:21,710,976...21,755,708
Ensembl chr  X:21,711,019...21,755,525
JBrowse link
G Sox15 SRY-box transcription factor 15 increases expression ISO butylparaben results in increased expression of SOX15 mRNA CTD PMID:17121429 NCBI chr10:56,260,514...56,263,503
Ensembl chr10:56,260,514...56,263,503
JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions
decreases expression
ISO NR3C1 protein promotes the reaction [butylparaben results in decreased expression of SPP1 mRNA]; PPARG protein inhibits the reaction [butylparaben results in decreased expression of SPP1 mRNA] CTD PMID:28527915 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Sptbn2 spectrin, beta, non-erythrocytic 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SPTBN2 mRNA CTD PMID:25607892 NCBI chr 1:219,964,429...220,006,811
Ensembl chr 1:219,964,429...220,005,068
JBrowse link
G Star steroidogenic acute regulatory protein decreases expression EXP butylparaben results in decreased expression of STAR mRNA; butylparaben results in decreased expression of STAR protein CTD PMID:18648085, PMID:26888303 NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
JBrowse link
G Stmn2 stathmin 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STMN2 mRNA CTD PMID:25607892 NCBI chr 2:95,424,251...95,471,900
Ensembl chr 2:95,424,251...95,472,115
JBrowse link
G Sts steroid sulfatase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of STS mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of STS mRNA CTD PMID:25607892 NCBI chr  X:45,420,418...45,428,748
Ensembl chr  X:45,420,596...45,428,750
JBrowse link
G Stx1b syntaxin 1B multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STX1B mRNA CTD PMID:25607892 NCBI chr 1:199,251,842...199,270,465
Ensembl chr 1:199,251,844...199,270,627
JBrowse link
G Stxbp1 syntaxin binding protein 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of STXBP1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STXBP1 mRNA CTD PMID:25607892 NCBI chr 3:11,823,779...11,885,479
Ensembl chr 3:11,823,785...11,885,417
JBrowse link
G Sult1e1 sulfotransferase family 1E member 1 decreases expression EXP butylparaben results in decreased expression of SULT1E1 mRNA; butylparaben results in decreased expression of SULT1E1 protein CTD PMID:26888303 NCBI chr14:22,070,861...22,089,264
Ensembl chr14:22,072,024...22,089,248
JBrowse link
G Syngap1 synaptic Ras GTPase activating protein 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SYNGAP1 mRNA CTD PMID:25607892 NCBI chr20:5,535,434...5,564,657
Ensembl chr20:5,535,432...5,564,437
JBrowse link
G Syp synaptophysin multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SYP mRNA CTD PMID:25607892 NCBI chr  X:15,694,699...15,709,244
Ensembl chr  X:15,695,566...15,707,436
JBrowse link
G Syt6 synaptotagmin 6 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SYT6 mRNA CTD PMID:25607892 NCBI chr 2:206,064,181...206,119,034
Ensembl chr 2:206,064,179...206,127,907
JBrowse link
G Tcea3 transcription elongation factor A3 increases expression ISO butylparaben results in increased expression of TCEA3 mRNA CTD PMID:17121429 NCBI chr 5:154,598,765...154,634,687
Ensembl chr 5:154,598,758...154,634,686
JBrowse link
G Tff1 trefoil factor 1 multiple interactions
increases expression
ISO Fulvestrant inhibits the reaction [butylparaben results in increased expression of TFF1 mRNA]; Silver inhibits the reaction [butylparaben results in increased expression of TFF1 mRNA] CTD PMID:16797915, PMID:17121429, PMID:22562034, PMID:23524099, PMID:29074358 NCBI chr20:9,892,124...9,895,984
Ensembl chr20:9,892,124...9,895,984
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of TGFB1 mRNA CTD PMID:25607892 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b increases expression ISO butylparaben results in increased expression of TNFRSF10A mRNA CTD PMID:24481588 NCBI chr15:51,433,853...51,464,215 JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B multiple interactions ISO butylparaben promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased secretion of TNFRSF11B protein] CTD PMID:31016361 NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
JBrowse link
G Tnfrsf1a TNF receptor superfamily member 1A increases expression ISO butylparaben results in increased expression of TNFRSF1A mRNA CTD PMID:24481588 NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
JBrowse link
G Tnfrsf21 TNF receptor superfamily member 21 decreases expression ISO butylparaben results in decreased expression of TNFRSF21 mRNA CTD PMID:24481588 NCBI chr 9:20,546,159...20,621,051
Ensembl chr 9:20,546,159...20,621,051
JBrowse link
G Tsc2 TSC complex subunit 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of TSC2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of TSC2 mRNA CTD PMID:25607892 NCBI chr10:13,962,006...13,996,684
Ensembl chr10:13,961,947...13,996,584
JBrowse link
G Tsnax translin-associated factor X multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of TSNAX mRNA CTD PMID:25607892 NCBI chr19:57,771,539...57,785,567
Ensembl chr19:57,771,398...57,785,543
JBrowse link
G Tspo translocator protein decreases expression EXP butylparaben results in decreased expression of TSPO mRNA CTD PMID:18648085 NCBI chr 7:124,460,358...124,470,610
Ensembl chr 7:124,460,358...124,470,609
JBrowse link
G Ubd ubiquitin D decreases expression ISO butylparaben results in decreased expression of UBD mRNA CTD PMID:17121429 NCBI chr20:1,876,175...1,878,126
Ensembl chr20:1,876,173...1,897,814
JBrowse link
G Unc5a unc-5 netrin receptor A multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of UNC5A mRNA CTD PMID:25607892 NCBI chr17:10,152,949...10,208,599
Ensembl chr17:10,153,994...10,208,360
JBrowse link
G Unc5b unc-5 netrin receptor B multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of UNC5B mRNA CTD PMID:25607892 NCBI chr20:30,339,680...30,406,593
Ensembl chr20:30,339,673...30,406,295
JBrowse link
G Unc5c unc-5 netrin receptor C multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of UNC5C mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of UNC5C mRNA CTD PMID:25607892 NCBI chr 2:247,045,813...247,397,483
Ensembl chr 2:247,248,407...247,397,483
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of VEGFA mRNA CTD PMID:25607892 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vill villin-like increases expression ISO butylparaben results in increased expression of VILL mRNA CTD PMID:17121429 NCBI chr 8:127,735,233...127,753,313
Ensembl chr 8:127,735,258...127,753,349
JBrowse link
G Vldlr very low density lipoprotein receptor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of VLDLR mRNA CTD PMID:25607892 NCBI chr 1:245,236,819...245,273,688
Ensembl chr 1:245,237,736...245,269,205
JBrowse link
G Wnk4 WNK lysine deficient protein kinase 4 increases expression ISO butylparaben results in increased expression of WNK4 mRNA CTD PMID:17121429 NCBI chr10:89,181,139...89,198,213
Ensembl chr10:89,181,165...89,198,213
JBrowse link
G Zfp397 zinc finger protein 397 increases expression ISO butylparaben results in increased expression of ZNF397 mRNA CTD PMID:17121429 NCBI chr18:15,856,841...15,865,574
Ensembl chr18:15,856,801...15,863,053
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19792
    chemical entity 19791
      atom 19788
        nonmetal atom 19662
          carbon atom 19560
            organic molecular entity 19560
              Butylparaben 240
Path 2
Term Annotations click to browse term
  CHEBI ontology 19792
    subatomic particle 19788
      composite particle 19788
        hadron 19788
          baryon 19788
            nucleon 19788
              atomic nucleus 19788
                atom 19788
                  main group element atom 19675
                    p-block element atom 19675
                      carbon group element atom 19571
                        carbon atom 19560
                          organic molecular entity 19560
                            Butylparaben 240
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.